Intellectual property boosts the development of China’s bioeconomy – Patent
The bioeconomy is a new economy based on the development, progress and popularization of life sciences and biotechnologies, as well as an integral part of the national economy. Recent years have seen the continued expansion of the industrial scale of China’s bioeconomy, as well as China’s major breakthroughs and innovations in basic biological research.
To keep pace with the accelerating development of global biotechnology and realize self-sufficiency and self-improvement in science-technology to higher levels, China has released the Fourteenth Five-Year Plan for the Development of Bio-economy in May 2022, proposing to build a national biotechnology strategy forces and break the bottlenecks of bio-economy development in an accelerated manner, thereby realizing self-sufficiency and self-improvement in science and technology. Notably, Traditional Chinese Medicine (TCM) is an important part of China’s bioeconomy, evidenced by the publication of the Fourteenth Five-Year Plan for the Development of Traditional Chinese Medicine in March 2022 with the aim of further strengthening the development of the bioeconomy.
“The innovative development of the bioeconomy is inseparable from the institutional guarantee of intellectual property (IP) and has opened a new path for the improvement of the IP governance system,” said Song Wei, executive director of the Institute. of Intellectual Property Research from the University of Science and Technology of China.
The fourteenth five-year plan for the development of the bioeconomy emphasizes the strengthening of intellectual property protection and the grooming of valuable patents to promote the realization of the value of intellectual property, as well as the transformation and application scientific and technological achievements.
Strengthen independent innovation, break the bottlenecks of biotech development
The development and progress of life sciences and biotechnologies are vital for the development of the bioeconomy. China is active in a wide range of innovation areas. China led the world in patent filings in the field of biological breeding at the end of September 2021. According to the landscape report on patents on COVID-19 vaccines and therapeutics published by the World Health Organization. Intellectual Property (WIPO) in March 2022, China is currently the leading originator of patent filings related to COVID-19 vaccines and therapeutics. All of these achievements demonstrate China’s accelerated efforts to achieve scientific and technological self-sufficiency and self-improvement in the bioeconomy at higher levels.
“Innovation is key to the development and future of the bioeconomy,” said Wang Xiang, deputy director general of the Department of Innovation and High-tech Development, National Development and Reform Commission. “Despite remarkable achievements in bio-economic innovation, China still faces many challenges and still needs to improve technologies in key areas and linkages.” Therefore, the fourteenth five-year plan for the development of the bioeconomy puts innovation at the forefront of the development of the bioeconomy, emphasizing that we must accelerate biotechnology innovation and industrialization and break the bottlenecks of development in a accelerated, in order to achieve self-confidence and self-improvement in biotechnology.
Innovation is also at the heart of the Fourteenth Five-Year Plan for the Development of Traditional Chinese Medicine. The plan clearly states that we should use modern technologies and methods, explore the essence of TCM, and develop new features and advantages in innovations, so as to promote the star development of TCM.
Promote chain integration, expand industrial scale of bio-economy
How to accelerate basic research and the industrialization of innovative technologies during this period to boost the innovative high-level development of biotechnologies? Intellectual property is essential.
To accelerate the industrialization of synthetic bio-manufacturing in China, CNIPA officially approved the establishment of the National Intellectual Property Exploitation Center for Synthetic Biology in April 2022. Drawing on the resources of the Institute of Tianjin Industrial Biotechnology, Chinese Academy of Sciences, the center has established the “Patent Pool for Synthetic Biology Enabling Technologies”, the “Patent Pool for Underlying Technologies of Corynebacterium Glutamicum” and other patent pools, continued to explore high-level underlying patented technologies, helped improve China’s synthetic biotech R&D capability, and established platforms to properly release patent portfolios to promote commercialization and the industrialization of synthetic biotechnologies.
Patent navigation projects also play an important role in industrializing innovations in key areas. In recent years, with emphasis on biomedicine and biohealth, organic animal husbandry and other industrial fields, regions such as Shanghai, Jiangsu and Heilongjiang have deployed patent browsing system and analyzed regional information on biotechnological patents to identify the competitive advantage of patented local technologies, thus guiding the choice of technical paths and the transformation of the industrial structure. The output value of biomedical industry in Shanghai and Jiangsu exceeded 700 billion yuan and 400 billion yuan respectively in 2021, showing the significant economic benefits generated by bio-patents.
“The bioeconomy’s innovation chain is long – from basic research in synthetic biology and brain science, to technical improvements in genetic sequencing and biological sensing, to product R&D and services. healthcare, all the links in the innovation chain are very important.” Song said. Continue to promote the integration of IP creation, application, protection, management and services with bio-economy innovation, and improve the management mechanism of the entire IP chain bioeconomy will provide stronger support for the development of the bioeconomy.
The AFD China newsletter is intended to provide information to our customers and business partners only. Information provided on the newsletter should not be considered professional advice and should not form the basis of any business decision.